San Diego-based MediciNova announced that it has raised $44M in a third round of funding. Funding came from Essex Woodlands Health Ventures, Aqua RIMCO, Biovision Life Science Fund, China Development Industrial Bank, Diamond Capital, Dr. Ci:Labo, Mizuho Securities, New Business Investment, NIF Ventures, Nippon Venture Capital, POSCO Bioventures, SMBC Capital, The University of Tokyo Capital, J.F.E. Hottinger & Co. and other investors. The company also said that is raised a Series B earlier this year of $29M. Medicinova licenses and commercializes pharmaceutical products from academic laboratories, and is currently pursuing drug targets focused on premature labor, cancer, asthma, and other conditions. More information »